Hydroxychloroquine linked to increase in COVID-19 deaths, heart risks
Ars Technica » Scientific Method 2020-05-22
Enlarge / A bottle and pills of Hydroxychloroquine. US President Donald Trump announced May 18 he has been taking hydroxychloroquine for almost two weeks as a preventative measure against COVID-19. (credit: Getty | George Frey)
Two closely related anti-malarial drugs championed by President Donald Trump as promising treatments for COVID-19 appear to substantially increase the risks of death and heart complications in patients hospitalized from the disease.
That’s according to the largest study yet on the topic, which involved more than 96,000 hospitalized COVID-19 patients on six continents. The peer-reviewed study, appearing Friday in The Lancet, was led by Mandeep Mehra, a professor of medicine at Harvard.
The drugs studied included chloroquine and its analogue hydroxychloroquine, which are used to treat autoimmune diseases such as lupus and rheumatoid arthritis, as well as malaria. Early laboratory work suggested that they also have potent anti-viral properties. But small clinical studies looking into potential benefits for COVID-19 patients have largely provided mixed and inconclusive results to this point.